News and Announcements
New Laboratory for Regenerative Medicine Opens
Posted August 2010 by Jason Schulte
Through the Clemson University Biomedical and Bioengineering Translational Research Program, the BTRL has secured space for a new Laboratory for Regenerative Medicine at the Greenville Hospital System University Medical Center Patewood campus in Greenville. The BTRL is one of only three research groups from the Clemson Department of Bioengineering to occupy the new facility. Work done in the Patewood laboratory will focus specifically on translational research opportunities, transferring technologies from the bench-top to the bedside.
Initial funding for the Patewood facility was provided through a $3.5 million grant from the state of South Carolina. To date, these funds have been used to install and outfit several research labs, a Center of Vascular Disease Diagnosis and Management, a medical library, a bioimaging facility, faculty, staff and student office space, and a high-tech conference room. These features constitute both Phase I and II of a proposed development plan for the facility, with a possible Phase III incorporating spaces for validational research and startup companies to foster further innovation.
Over the past few months, members of the BTRL have been actively participating in the setup of the new laboratory, installing equipment and supplies in preparation for the first studies which will be undertaken there. Work in the lab is anticipated to begin in late October, and will focus on generating preliminary data for several ongoing projects.
Members of the BTRL will be working alongside their colleagues from the Clemson Department of Bioengineering, as well as those from its other partner groups in the Clemson University Biomedical and Bioengineering Translational Research Program, the Institute for Vascular Health of the Greenville Hospital System and the Orthopaedic Research Foundation of the Carolinas. The BTRL is privileged to find itself involved in such a collaborative effort, and its members are committed to using this opportunity to further the development of cell and tissue-based therapies for cardiovascular and orthopaedic pathologies.
